West Pharmaceutical Services Inc (NYSE: WST)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000105770
Market Cap 17.69 Bn
P/B 18.80
P/E 133.13
P/S 12.54
ROIC (Qtr) 14.37
Div Yield % 0.26
Rev 1y % (Qtr) 7.73
Total Debt (Qtr) 297.60 Mn
Debt/Equity (Qtr) 0.10

About

West Pharmaceutical Services Inc. (WST) is a leading global manufacturer specializing in the production of advanced, high-quality, and integrated containment and delivery systems for injectable drugs and healthcare products. The company operates in two primary business segments: Proprietary Products and Contract-Manufactured Products. These segments offer a variety of solutions, including primary packaging, containment systems, reconstitution and transfer systems, drug delivery systems, contract manufacturing, analytical lab services, and integrated...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 693.80M provides robust 2.33x coverage of total debt 297.60M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 628.50M provide 29.37x coverage of short-term debt 21.40M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 3.99B provides 13.39x coverage of total debt 297.60M, indicating robust asset backing and low credit risk.
  • Operating cash flow of 693.80M provides strong 32.42x coverage of stock compensation 21.40M, indicating sustainable incentive practices.
  • Strong operating cash flow of 693.80M provides 1.87x coverage of SG&A expenses 371.90M, showing efficient operational cost management.

Bear case

  • Operating cash flow of 693.80M barely covers its investment activities of (314.60M), with a coverage ratio of -2.21, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Operating cash flow of 693.80M provides thin coverage of dividend payments of (60.70M) with a -11.43 ratio, suggesting potential dividend sustainability issues if operational performance deteriorates.
  • Investment activities of (314.60M) provide weak support for R&D spending of 71M, which is -4.43x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Free cash flow of 379.10M represents just -421.22x of debt issuance (900000), suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Tax assets of 27.90M provide limited offset against tax liabilities of 56.10M, which is 0.50x, indicating potential future cash flow pressure from tax obligations.

Segments Breakdown of Revenue (2024)

Geographical Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 174.27 Bn 61.02 17.31 0.00 Bn
2 BDX Becton Dickinson & Co 59.72 Bn 37.77 3.14 19.18 Bn
3 RMD Resmed Inc 39.76 Bn 26.76 7.37 0.85 Bn
4 ALC Alcon Inc 38.93 Bn 37.18 3.82 5.24 Bn
5 WST West Pharmaceutical Services Inc 17.69 Bn 133.13 12.54 0.30 Bn
6 HOLX Hologic Inc 16.81 Bn 30.91 4.07 2.52 Bn
7 COO Cooper Companies, Inc. 16.37 Bn 43.67 4.00 2.51 Bn
8 ALGN Align Technology Inc 13.73 Bn 36.29 3.45 0.09 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 4.33 2.75
EV to Cash from Ops. EV/CFO 103.22 39.87
EV to Debt EV to Debt 59.72 27.09
EV to EBIT EV/EBIT 89.14 32.86
EV to EBITDA EV/EBITDA 63.32 19.31
EV to Free Cash Flow [EV/FCF] EV/FCF 288.54 0.88
EV to Market Cap EV to Market Cap 1.00 -4.26
EV to Revenue EV/Rev 12.60 252.61
Price to Book Value [P/B] P/B 18.80 6.13
Price to Earnings [P/E] P/E 133.13 184.03
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 8.10 -1.09
Dividend Payout Ratio % Div Payout % (Qtr) 12.40 1.36
Dividend per Basic Share Div per Share (Qtr) 0.84 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 16.00 8.74
Interest Coverage Int. cover (Qtr) -6,167.00 -117.83
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 17.36 -53.47
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 28.03 414.02
Dividend Growth (1y) % Div 1y % (Qtr) 5.00 -1.48
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -2.40 -57.42
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 4.32 -106.89
EBIT Growth (1y) % EBIT 1y % (Qtr) 1.13 -37.00
EBT Growth (1y) % EBT 1y % (Qtr) 1.98 -42.63
EPS Growth (1y) % EPS 1y % (Qtr) -0.29 -15.05
FCF Growth (1y) % FCF 1y % (Qtr) 17.88 56.29
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 7.04 67.95
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.74 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.06 0.03
Cash Ratio Cash Ratio (Qtr) 0.99 2.51
Current Ratio Curr Ratio (Qtr) 2.87 7.80
Debt to Equity Ratio Debt/Equity (Qtr) 0.10 0.55
Interest Cover Ratio Int Coverage (Qtr) -6,167.00 -117.83
Times Interest Earned Times Interest Earned (Qtr) -6,167.00 -117.83
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 25.90 -2,368.59
EBIT Margin % EBIT Margin % (Qtr) 20.43 -2,472.59
EBT Margin % EBT Margin % (Qtr) 20.44 -2,442.52
Gross Margin % Gross Margin % (Qtr) 35.60 30.06
Net Profit Margin % Net Margin % (Qtr) 16.30 -2,438.49